Extended Data Fig. 4: Bliss independence model evaluating the synergistic effect between lenvatinib or sorafenib with gefitinib in liver cancer cells. | Nature

Extended Data Fig. 4: Bliss independence model evaluating the synergistic effect between lenvatinib or sorafenib with gefitinib in liver cancer cells.

From: EGFR activation limits the response of liver cancer to lenvatinib

Extended Data Fig. 4

The Bliss independence model was applied to the quantification data of colony-formation experiments in Extended Data Figs. 2g–l, 3g–l. The data in the untreated condition (no lenvatinib or gefitinib) were normalized as 0, indicating no inhibition of cell viability. Then, the additive scores (blissAdd) were generated by multiplying the normalized effect of the two single drugs. We further calculated the reduction in viability by subtracting the mean of the blissAdd from the mean of the measured combination scores (measured). The green background indicates the synergistic effect with P ≤ 0.05 and when the reduction in viability is more than 10%. af, Bliss independence analysis for the combination of gefitinib and lenvatinib shown in Extended Data Fig. 2g–l. gl, Bliss independence analysis for the combination of gefitinib and sorafenib shown in Extended Data Fig. 3g–l. Data are mean ± s.e.m., n = 3 independent experiments. P values were determined by unpaired two-sided Student’s t-test

Source data.

Back to article page